Keyphrases
Adaptive Design
11%
Adjudication Committee
11%
Adult Patients
11%
Associated Complications
11%
Chemotherapy
55%
Efficacy Endpoint
11%
EudraCT
11%
Follow-up Data
11%
Fourth Dose
11%
Group Assignment
11%
Hematological Malignancies
55%
Herpes Zoster
88%
Herpes Zoster Incidence
11%
Immunocompromised Patients
100%
Injection Site Reaction
11%
Interim Analysis
11%
Irradiation
22%
Laboratory Workers
11%
Malignancy
100%
Merck
11%
Modified Intention-to-treat
22%
Multicenter Trial
11%
One Dose
22%
Patients with Hematological Malignancies
11%
Phase II Trial
100%
Placebo
66%
Placebo Groups
11%
Placebo-controlled
11%
Primary Safety
11%
Randomized Double-blind
100%
Risk Difference
11%
Safety Endpoints
22%
Serious Adverse Events
33%
Solid Tumors
88%
Success Criteria
11%
Treatment Group
22%
Tumor Malignancy
88%
Vaccine Effectiveness
22%
Varicella Vaccine
100%
Medicine and Dentistry
Adaptive Clinical Trial
11%
Adverse Event
33%
Arm
100%
Attributable Risk
11%
Cancer
100%
Disseminated Herpes Zoster
100%
Hematologic Malignancy
66%
Immunocompromised Patient
100%
Inactivated Vaccine
22%
Injection Site Reaction
11%
Intention-to-Treat Analysis
22%
Interim Analysis
11%
Placebo
88%
Solid Malignant Neoplasm
88%
Treatment Group
22%
Vaccine Efficacy
22%
Varicella Zoster Virus
100%
Virus Vaccine
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adaptive Clinical Trial
11%
Adverse Event
33%
Chemotherapy
55%
Hematologic Malignancy
66%
Herpes Zoster
100%
Immunocompromised Patient
100%
Inactivated Vaccine
22%
Injection Site Reaction
11%
Placebo
88%
Solid Malignant Neoplasm
88%
Treatment Group
22%
Vaccine Efficacy
22%
Varicella Zoster Virus
100%
Virus Vaccine
100%